• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载脂蛋白M作为冠状动脉疾病生物标志物的评估。

Evaluation of apolipoprotein M as a biomarker of coronary artery disease.

作者信息

Su Weiqiang, Jiao Guoqing, Yang Chengjian, Ye Yizhou

机构信息

Department of Cardiovascular Surgery, Affiliated Wuxi 2nd People's Hospital, Nanjing Medical University, Jiangsu, People's Republic of China.

出版信息

Clin Biochem. 2009 Mar;42(4-5):365-70. doi: 10.1016/j.clinbiochem.2008.11.010. Epub 2008 Dec 3.

DOI:10.1016/j.clinbiochem.2008.11.010
PMID:19100249
Abstract

OBJECTIVE

To investigate the possible role of apolipoprotein M (ApoM) in the development of coronary artery disease (CAD).

DESIGN AND METHODS

Case-controlled study, which consisted of 118 CAD patients and 255 unrelated subjects used as control group. Plasma concentration of ApoM was determined by dot blot, severity of CAD was expressed with Gensini score or the numbers of lesioned coronary arteries, and serum lipid levels were also measured.

RESULTS AND DISCUSSION

Our study shows the mean level of plasma ApoM is 1.3757+/-0.1493 ODu mm(-2) in CAD patients, while it is 1.3502+/-0.1288 ODu mm(-2) in control group, and there are significant differences in plasma level of ApoM between two groups (t=0.032, P<0.05). Concentration of plasma ApoM is positively associated with plasma total cholesterol (r=0.38, P=0.025), high density lipoprotein cholesterol (r=0.29, P=0.03), low density lipoprotein cholesterol (r=0.16, P=0.03) and apolipoproein A-I (r=0.24, P=0.03). Multiple logistic and linear regression analysis showed that plasma concentration of ApoM did not correlate either with the number of lesioned coronaries or the Gensini score after adjusted for conventional cardiovascular risk factors (P>0.05, respectively).

CONCLUSION

The findings suggest that ApoM could not be an independent risk factor but a biomarker of CAD.

摘要

目的

探讨载脂蛋白M(ApoM)在冠状动脉疾病(CAD)发生发展中的可能作用。

设计与方法

病例对照研究,包括118例CAD患者和255名无亲缘关系的受试者作为对照组。采用斑点印迹法测定血浆ApoM浓度,用Gensini评分或病变冠状动脉数量表示CAD的严重程度,并测定血脂水平。

结果与讨论

我们的研究显示,CAD患者血浆ApoM的平均水平为1.3757±0.1493 ODu mm(-2),而对照组为1.3502±0.1288 ODu mm(-2),两组间血浆ApoM水平存在显著差异(t = 0.032,P < 0.05)。血浆ApoM浓度与血浆总胆固醇(r = 0.38,P = 0.025)、高密度脂蛋白胆固醇(r = 0.29,P = 0.03)、低密度脂蛋白胆固醇(r = 0.16,P = 0.03)和载脂蛋白A-I(r = 0.24,P = 0.03)呈正相关。多元逻辑回归和线性回归分析显示,在调整传统心血管危险因素后,血浆ApoM浓度与病变冠状动脉数量或Gensini评分均无相关性(P均> 0.05)。

结论

研究结果表明,ApoM不是CAD的独立危险因素,而是CAD的一个生物标志物。

相似文献

1
Evaluation of apolipoprotein M as a biomarker of coronary artery disease.载脂蛋白M作为冠状动脉疾病生物标志物的评估。
Clin Biochem. 2009 Mar;42(4-5):365-70. doi: 10.1016/j.clinbiochem.2008.11.010. Epub 2008 Dec 3.
2
A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese.汉族人群载脂蛋白M基因T-778C多态性与冠状动脉疾病关系的前瞻性评估
Clin Biochem. 2007 Oct;40(15):1108-12. doi: 10.1016/j.clinbiochem.2007.04.023. Epub 2007 Jul 4.
3
Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.载脂蛋白M预测前β-HDL的形成:对2型糖尿病和非糖尿病受试者的研究。
J Intern Med. 2009 Sep;266(3):258-67. doi: 10.1111/j.1365-2796.2009.02095.x. Epub 2009 Mar 7.
4
A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.一项基于三级护理医院的针对已确诊冠状动脉疾病的常规风险因素(包括血脂谱)的研究。
Indian Heart J. 2003 May-Jun;55(3):234-40.
5
An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis.接受腹膜透析治疗的终末期肾病(ESRD)患者的冠状动脉钙化评分、血脂谱与慢性炎症相关标志物之间的关联。
Am J Kidney Dis. 2003 Jan;41(1):203-11. doi: 10.1053/ajkd.2003.50005.
6
Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease.用于识别多支冠状动脉疾病患者的新型动脉粥样硬化标志物。
Kardiol Pol. 2008 Nov;66(11):1173-80; discussion 1181-2.
7
Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease.低密度脂蛋白(LDL),其中包括载脂蛋白A-I(apoAI-LDL)作为冠状动脉疾病的一种新标志物。
Clin Chim Acta. 2008 Nov;397(1-2):42-7. doi: 10.1016/j.cca.2008.07.014. Epub 2008 Jul 18.
8
Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.幽门螺杆菌(H. pylori)感染与冠状动脉疾病:经皮冠状动脉腔内血管成形术后幽门螺杆菌根除对冠状动脉管腔的影响。人冠状动脉粥样硬化斑块中幽门螺杆菌特异性DNA的检测。
J Physiol Pharmacol. 2001 Aug;52(1 Suppl 1):3-31.
9
Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects.
J Nutr Biochem. 2004 Oct;15(10):579-82. doi: 10.1016/j.jnutbio.2004.03.001.
10
Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.法裔加拿大人早发性冠状动脉疾病中的代谢因素聚集、脂蛋白胆固醇、载脂蛋白B、脂蛋白(a)和载脂蛋白E表型
Can J Cardiol. 1997 Mar;13(3):253-60.

引用本文的文献

1
Genetic Susceptibility to Hidradenitis Suppurativa and Predisposition to Cardiometabolic Disease.化脓性汗腺炎的遗传易感性与心血管代谢疾病的易感性
JAMA Dermatol. 2025 Jan 1;161(1):22-30. doi: 10.1001/jamadermatol.2024.3779.
2
Regulation of cellular and systemic sphingolipid homeostasis.细胞和全身鞘脂稳态的调节。
Nat Rev Mol Cell Biol. 2024 Oct;25(10):802-821. doi: 10.1038/s41580-024-00742-y. Epub 2024 Jun 18.
3
Lipocalin family proteins and their diverse roles in cardiovascular disease.脂质运载蛋白家族蛋白及其在心血管疾病中的多种作用。
Pharmacol Ther. 2023 Apr;244:108385. doi: 10.1016/j.pharmthera.2023.108385. Epub 2023 Mar 24.
4
HDL Composition, Heart Failure, and Its Comorbidities.高密度脂蛋白成分、心力衰竭及其合并症
Front Cardiovasc Med. 2022 Mar 8;9:846990. doi: 10.3389/fcvm.2022.846990. eCollection 2022.
5
Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE-deficient mice.阿托伐他汀通过减弱高脂血症载脂蛋白E缺乏小鼠的肝X受体α表达来上调载脂蛋白M的表达。
Exp Ther Med. 2018 Nov;16(5):3785-3792. doi: 10.3892/etm.2018.6694. Epub 2018 Sep 4.
6
Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL.高密度脂蛋白的抗动脉粥样硬化功能及新型疗法的研究进展
Int J Mol Sci. 2015 Jul 28;16(8):17245-72. doi: 10.3390/ijms160817245.
7
Decreased activities of apolipoprotein m promoter are associated with the susceptibility to coronary artery diseases.载脂蛋白 M 启动子活性降低与冠心病易感性相关。
Int J Med Sci. 2014 Feb 20;11(4):365-72. doi: 10.7150/ijms.7696. eCollection 2014.
8
Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes.载脂蛋白 M 基因(APOM)多态性改变 2 型糖尿病的代谢和疾病特征。
PLoS One. 2011 Feb 24;6(2):e17324. doi: 10.1371/journal.pone.0017324.